Drugs and Devices

FDA approves Nulojix for prevention of acute rejection in kidney transplant patients

The U.S. Food and Drug Administration (FDA) has approved Nulojix (belatacept) for prevention of acute rejection in adult patients who have had a kidney transplant. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares